Ruth Lim, MD
Assistant Professor of Radiology and Biomedical ImagingCards
About
Research
Publications
2025
Summary of the 2024 Update of the North American Guidelines for Pediatric Administered Radiopharmaceutical Activities.
Treves S, Fahey F, Valencia V, Burchell N, Burton C, Czachowski M, Grant F, Lai H, Lim R, Nadel H, Pampaloni M, Pandit-Taskar N, Parisi M, Seghers V, Shah S, Shulkin B, States L, Vali R, Yoo D, Zukotynski K. Summary of the 2024 Update of the North American Guidelines for Pediatric Administered Radiopharmaceutical Activities. Journal Of Nuclear Medicine 2025, jnumed.125.270478. PMID: 41344855, DOI: 10.2967/jnumed.125.270478.Peer-Reviewed Original ResearchJoint EANM/SNMMI procedural guideline for paediatric bone hybrid imaging with 99mTc-labelled radiopharmaceuticals and [18F]fluoride
Rogasch J, Vali R, Borgwardt L, States L, Lim R, Nadel H, Piccardo A, Roca-Bielsa I, Biassoni L, Zucchetta P, Bar-Sever Z. Joint EANM/SNMMI procedural guideline for paediatric bone hybrid imaging with 99mTc-labelled radiopharmaceuticals and [18F]fluoride. EANM Innovation 2025, 1: 100009. DOI: 10.1016/j.eanmi.2025.100009.Peer-Reviewed Original ResearchPediatric PET/MRI: Imaging Techniques, Indications, and Clinical Implementation.
Gatidis S, Ponisio M, Borgwardt L, Cain T, Francis P, Hamdi M, Johnson G, Kurch L, Laforest R, Lim R, McConathy J, Mody T, Nevo E, Pandit-Taskar N, Qi J, States L, Zucchetta P, Nadel H. Pediatric PET/MRI: Imaging Techniques, Indications, and Clinical Implementation. RadioGraphics 2025, 45: e240105. PMID: 41100355, DOI: 10.1148/rg.240105.Peer-Reviewed Original Research2024 Update of the North American Consensus Guidelines for Pediatric Administered Radiopharmaceutical Activities.
Treves S, Fahey F, Ferrer Valencia V, Burchell N, Burton C, Czachowski M, Grant F, Lai H, Lim R, Nadel H, Pampaloni M, Pandit-Taskar N, Parisi M, Seghers V, Shah S, Shulkin B, States L, Vali R, Yoo D, Zukotynski K. 2024 Update of the North American Consensus Guidelines for Pediatric Administered Radiopharmaceutical Activities. Journal Of Nuclear Medicine Technology 2025, 53: 193-197. PMID: 40664486, DOI: 10.2967/jnmt.125.270161.Peer-Reviewed Original ResearchConceptsNorth American consensus guidelinesAmerican consensus guidelinesConsensus guidelinesNuclear medicine expertsRadiopharmaceutical activityPediatric nuclear medicinePractice of pediatric nuclear medicineNuclear medicineAdministered radiopharmaceutical activityRadiopharmaceutical agentRoutine usePET imagingClinical practiceDiagnostic nuclear medicineMedicine expertsWorking GroupImpact of advancesPETGuidelinesModeling inter‐reader variability in clinical target volume delineation for soft tissue sarcomas using diffusion model
Dong Y, Marin T, Zhuo Y, Najem E, Beddok A, Rozenblum L, Moteabbed M, Grogg K, Xing F, Woo J, Chen Y, Lim R, Liu X, Ma C, Fakhri G. Modeling inter‐reader variability in clinical target volume delineation for soft tissue sarcomas using diffusion model. Medical Physics 2025, 52: e17865. PMID: 40317577, PMCID: PMC12424543, DOI: 10.1002/mp.17865.Peer-Reviewed Original ResearchClinical target volumeGross tumor volumeClinical target volume delineationSoft tissue sarcomasInter-reader variabilityTissue sarcomasClinical target volume contoursMagnetic resonance imagingCTV delineationTarget volume delineationComputed tomographyTreatment of soft tissue sarcomasFluorodeoxyglucose positron emission tomographyCTV contoursTarget volumeVolume delineationT1-weighted magnetic resonance imagingRadiotherapy treatmentEnergy distanceHigh Dice indexPositron emission tomographyTumor volumeMicroscopic spreadFDG-PETTreatment planningGross tumor volume confidence maps prediction for soft tissue sarcomas from multi-modality medical images using a diffusion model
Dong Y, Marin T, Zhuo Y, Najem E, Moteabbed M, Xing F, Beddok A, Lahoud R, Rozenblum L, Ding Z, Liu X, Grogg K, Woo J, Chen Y, Lim R, Ma C, Fakhri G. Gross tumor volume confidence maps prediction for soft tissue sarcomas from multi-modality medical images using a diffusion model. Physics And Imaging In Radiation Oncology 2025, 33: 100734. PMID: 40123775, PMCID: PMC11926426, DOI: 10.1016/j.phro.2025.100734.Peer-Reviewed Original ResearchGross tumor volumeSoft tissue sarcomasTissue sarcomasGross tumor volume delineationManual GTV delineationsMagnetic resonance imagingComputed tomographyFluorodeoxyglucose positron emission tomographyGTV delineationT1-weighted magnetic resonance imagingSingle-modePositron emission tomographyMulti-modal medical imagesTumor volumeIntra-reader variabilityFDG-PETTreatment planningSarcomaEmission tomographyImaging modalitiesResonance imagingDiffusion modelDice indexReader variabilityPatients
2024
Review of the Clinical and Technical Aspects of 99mTc-Dimercaptosuccinic Acid Renal Imaging: The Comeback “Kit”
Lim R, Kwatra N, Ferrer Valencia V, Collins K, Vali R, Fahey F, Treves S. Review of the Clinical and Technical Aspects of 99mTc-Dimercaptosuccinic Acid Renal Imaging: The Comeback “Kit”. Journal Of Nuclear Medicine Technology 2024, 52: jnmt.123.267185. PMID: 39137980, DOI: 10.2967/jnmt.123.267185.Peer-Reviewed Original ResearchConceptsTc-DMSAFood and Drug AdministrationDrug AdministrationRenal cortical defectsNuclear medicine cliniciansU.S. Food and Drug AdministrationRenal functionDisorders affecting childrenRenal imagingImaging specialistsCortical defectsDimercaptosuccinic acidClinical needImaging practicesAdministrationImaging methodsKitAdultsChildrenThe role of 18F-FDG PET in minimizing variability in gross tumor volume delineation of soft tissue sarcomas
Najem E, Marin T, Zhuo Y, Lahoud R, Tian F, Beddok A, Rozenblum L, Xing F, Moteabbed M, Lim R, Liu X, Woo J, Lostetter S, Lamane A, Chen Y, Ma C, El Fakhri G. The role of 18F-FDG PET in minimizing variability in gross tumor volume delineation of soft tissue sarcomas. Radiotherapy And Oncology 2024, 194: 110186. PMID: 38412906, PMCID: PMC11042980, DOI: 10.1016/j.radonc.2024.110186.Peer-Reviewed Original ResearchGross tumor volume delineationGross tumor volumeDice similarity coefficientF-FDG PET imagingSoft tissue sarcomasInter-reader variabilityGTV delineationRadiation therapy treatment planningF-FDGF-FDG PETTherapy treatment planningPerformance level estimationTumor volume delineationTissue sarcomasPET imagingVolume delineationSimultaneous truthHausdorff distanceDice similarity coefficient scoreAccurate gross tumor volumeImaging modality groupsWilcoxon signed-rank testStatistically significant decreaseSigned-rank testTumor volume
2023
A Comprehensive Primer on Radiation Oncology for Non-Radiation Oncologists
Beddok A, Lim R, Thariat J, Shih H, Fakhri G. A Comprehensive Primer on Radiation Oncology for Non-Radiation Oncologists. Cancers 2023, 15: 4906. PMID: 37894273, PMCID: PMC10605284, DOI: 10.3390/cancers15204906.Peer-Reviewed Original ResearchProton therapyRadiation therapyRadiation oncologistsIntensity-modulated proton therapyNon-oncologistsNon-radiation oncologistsImage-guided RTFollow-upExternal beam therapyArc therapyThree-dimensional conformal RTCT simulationPatient alignmentTarget volumeIntensity-modulated RTRT planningCompletion of RTPotential late effects of treatmentMedical physicistsLifelong follow-upLate effects of treatmentPatient follow-upBeam therapyNon-radiativeOptimize treatment outcomesOutcomes After Preoperative Chemoradiation With or Without Pazopanib in Non-Rhabdomyosarcoma Soft Tissue Sarcoma: A Report From Children's Oncology Group and NRG Oncology
Weiss A, Chen Y, Scharschmidt T, Xue W, Gao Z, Black J, Choy E, Davis J, Fanburg-Smith J, Kao S, Kayton M, Kessel S, Lim R, Million L, Okuno S, Ostrenga A, Parisi M, Pryma D, Randall R, Rosen M, Shulkin B, Terezakis S, Venkatramani R, Zambrano E, Wang D, Hawkins D, Spunt S. Outcomes After Preoperative Chemoradiation With or Without Pazopanib in Non-Rhabdomyosarcoma Soft Tissue Sarcoma: A Report From Children's Oncology Group and NRG Oncology. Journal Of Clinical Oncology 2023, 41: 4842-4848. PMID: 37523624, PMCID: PMC10852395, DOI: 10.1200/jco.23.00045.Peer-Reviewed Original ResearchConceptsNon-rhabdomyosarcoma soft tissue sarcomasSoft tissue sarcomasRegimen BPreoperative chemoradiationRegimen ATissue sarcomasPathological responseMedian survivor follow-upComplete pathologic response ratePathological response rateEvent-free survivalPhase II studyPrimary end pointChildren's Oncology GroupIntent-to-treat analysisSurvivor follow-upNon-rhabdomyosarcomasPreoperative radiotherapyPrimary resectionOverall survivalOncology GroupII studyClinical trial updateNRG OncologyEligible patients
Get In Touch
Contacts
Email